Identifying risks and solutions: study uncovers correlates of protection against COVID-19 NatureComms covid COVID19 SARSCoV2 protection vaccine
By Susha Cheriyedath, M.Sc.Aug 2 2023Reviewed by Lily Ramsey, LLM A recent study published in the Nature Communications Journal identified correlates of protection in 607 healthy individuals who have received three doses of Pfizer- BNT162b2 vaccine against coronavirus disease 2019 variants.
The Israeli Ministry of Health recommended the fourth dose of the Pfizer vaccine for immunocompromised groups and healthcare professionals, with epidemiological studies showing its efficacy in reducing infection rates. COPs are immune markers that predict vaccine efficacy. Related StoriesImmunogenicity testing was conducted on 74 subjects with the lowest and highest antibodies. The Cox proportional hazards model assessed infection risk and vaccination efficacy .
In the first trial to report COPs for the Pfizer vaccine booster doses and against Omicron B.A1, neutralizing antibody titers indicated protection against Omicron B.A127 after two doses of the Pfizer-BioNTech vaccine. In addition, these titers predicted protection against Omicron B.A1.